Long non-coding RNA SNHG7 serves as a diagnostic biomarker for acute coronary syndrome and its predictive value for the clinical outcome after percutaneous coronary intervention

TL;DR

This study explores how the long non-coding RNA SNHG7 can help diagnose and predict outcomes in patients with acute coronary syndrome after a specific heart procedure.

Contribution

The study identifies SNHG7 as a novel biomarker for diagnosing acute coronary syndrome and predicting clinical outcomes after PCI.

Findings

SNHG7 is highly expressed in acute coronary syndrome and its subtypes.

High SNHG7 expression correlates with increased risk of adverse outcomes after PCI.

SNHG7 is an independent biomarker for predicting prognosis in ACS patients.

Abstract

Acute coronary syndrome (ACS) is one of the common causes of cardiovascular death. The related lncRNAs were novel approaches for early diagnosis and intervention. This paper focused on the clinical function of SNHG7 for patients after PCI.

The expression of SNHG7 was assessed in ACS patients. The predictive roles of SNHG7 were unveiled by the ROC curve. The relationship between SNHG7 and Gensini scores was judged by Pearson analysis. One-year follow-up was conducted and all patients were catalogued into different groups based on the prognosis. The qRT-PCR, K-M curve, and Cox regression analysis were performed to document the prognostic significance of SNHG7.

SNHG7 was highly expressed in ACS and its three subtypes. SNHG7 showed a certain value in predicting ACS, UA, NSTEMI, and STEMI. Gensini is a closely correlated indicator of SNHG7. The declined expression of SNHG7 was observed in the non-MACE and survival groups. The risk of MACE and death was increased in the group with high expression of SNHG7. SNHG7 was an independent biomarker in patients with ACS after PCI.

SNHG7 might be a diagnostic and prognostic tool for ACS patients.

Figures